Cargando…

Fatty Liver Disease and Cardiovascular Risk: Impact of Metabolic Dysfunctions

Detalles Bibliográficos
Autor principal:	Lee, Jung Il
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Editorial Office of Gut and Liver 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289830/ https://www.ncbi.nlm.nih.gov/pubmed/35843683 http://dx.doi.org/10.5009/gnl220276

Ejemplares similares

Comparing the Mortality Risk between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease
por: Jung, Han Na, et al.
Publicado: (2023)

Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease
por: Alam, Shahinul, et al.
Publicado: (2021)

Anxiety and Depression in Metabolic-Dysfunction-Associated Fatty Liver Disease and Cardiovascular Risk
por: Ismaiel, Abdulrahman, et al.
Publicado: (2022)

Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention
por: Zhou, Xiao-Dong, et al.
Publicado: (2022)

Unraveling Metabolic Dysfunction-Associated Fatty Liver Disease: Refining Sub-Phenotypes for Resolving Its Heterogeneity
por: Park, Jung Gil
Publicado: (2023)

From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials
por: Yeh, Ming-Lun, et al.
Publicado: (2023)

The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease
por: Yilmaz, Yusuf, et al.
Publicado: (2023)

Editorial: The Metabolic (Dysfunction) Associated Fatty Liver Disease (MAFLD)-Non-Alcoholic Fatty Liver Disease (NAFLD) Debate: A Forced Consensus and The Risk of a World Divide
por: Méndez-Sánchez, Nahum, et al.
Publicado: (2022)

Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology
por: Yoon, Eileen Laurel, et al.
Publicado: (2023)

Metabolic dysfunction-associated fatty liver disease: from basic research to clinical application
por: Yang, Ruixu, et al.
Publicado: (2022)

Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease
por: Han, Eugene, et al.
Publicado: (2022)

Metabolic Dysfunction-Associated Fatty Liver Disease Better Predicts Incident Cardiovascular Disease
por: Jeong, Seogsong, et al.
Publicado: (2022)

Metabolic-associated Fatty Liver Disease
por: Zheng, Ming-Hua
Publicado: (2021)

The EMRG Consortium: a gate to identify the burden of metabolic (dysfunction)-associated fatty liver disease in Egypt
por: Fouad, Yasser, et al.
Publicado: (2021)

Higher cardiovascular risk scores and liver fibrosis risk estimated by biomarkers in patients with metabolic-dysfunction-associated fatty liver disease
por: Salgado Alvarez, Giovanni Alejandro, et al.
Publicado: (2022)

Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis
por: Wen, Wen, et al.
Publicado: (2022)

MBOAT7 rs641738 variant in metabolic-dysfunction-associated fatty liver disease and cardiovascular risk
por: Ismaiel, Abdulrahman, et al.
Publicado: (2023)

Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex
por: Matsubayashi, Yasuhiro, et al.
Publicado: (2022)

Fatty Liver Disease: Metabolic, Genetic, or Both?
por: Zoller, Heinz, et al.
Publicado: (2020)

Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
por: Song, Byeong Geun, et al.
Publicado: (2023)

Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact
por: Tang, Si-Ying, et al.
Publicado: (2023)

Insidious danger for young adults: Metabolic (dysfunction)-associated fatty liver disease
por: Kaya, Eda, et al.
Publicado: (2022)

Update cognition of nonalcoholic fatty liver disease/metabolism‐associated fatty liver disease
por: Gu, Weijun, et al.
Publicado: (2022)

Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease
por: Moon, Joon Ho, et al.
Publicado: (2022)

Editorial: The Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD) and Non-Alcoholic Fatty Liver Disease (NAFLD) Debate: Why the American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL) Consensus Process is Not Representative
por: Fouad, Yasser Mahrous, et al.
Publicado: (2022)

From the liver to the heart: Cardiac dysfunction in obese children with non-alcoholic fatty liver disease
por: Di Sessa, Anna, et al.
Publicado: (2017)

Fatty liver with metabolic disorder, such as metabolic dysfunction‐associated fatty liver disease, indicates high risk for developing diabetes mellitus
por: Miyake, Teruki, et al.
Publicado: (2022)

Metabolic syndrome cardiovascular risk prevention by omega-3 polyunsaturated fatty acids
por: Bäck, Magnus, et al.
Publicado: (2023)

Relationship between Adipokines and Cardiovascular Ultrasound Parameters in Metabolic-Dysfunction-Associated Fatty Liver Disease
por: Ismaiel, Abdulrahman, et al.
Publicado: (2021)

Potential Effect of a Selective Peroxisome Proliferator-activated Receptor Alpha Modulator on Metabolic Dysfunction-associated Fatty Liver Disease
por: Kamimura, Hiroteru, et al.
Publicado: (2021)

Metabolic Dysfunction-Associated Fatty Liver Disease Is Associated with the Risk of Incident Cardiovascular Disease: A Prospective Cohort Study in Xinjiang
por: Guo, Yanbo, et al.
Publicado: (2022)

Cardiovascular Autonomic Dysfunction in Patients of Nonalcoholic Fatty Liver Disease
por: Kumar, Mavidi Sunil, et al.
Publicado: (2016)

Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan
por: Yoneda, Masato, et al.
Publicado: (2021)

Shaping the future of pediatric liver health: unraveling the impact of the new metabolic-associated fatty liver disease definition
por: Ciardullo, Stefano, et al.
Publicado: (2023)

Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD)
por: Méndez-Sánchez, Nahum, et al.
Publicado: (2021)

Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes
por: Lim, Tae Seop, et al.
Publicado: (2023)

Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
por: Han, A Lum
Publicado: (2022)

Smoking Increases the Risk of Hepatocellular Carcinoma and Cardiovascular Disease in Patients with Metabolic-Associated Fatty Liver Disease
por: Yoo, Jeong-Ju, et al.
Publicado: (2023)

Impact of nonalcoholic fatty liver disease on the risk of metachronous colorectal neoplasia after polypectomy
por: Kim, Nam Hee, et al.
Publicado: (2021)

Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor
por: Platek, Anna E., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7f0qrr3i2nd68899kl17ik4e30